Sermorelin is a 29-amino acid synthetic analogue of the first 29 residues of endogenous GHRH, representing the shortest fully active GHRH fragment. It was previously FDA-approved for paediatric growth disorders before being commercially withdrawn. Its key research interest lies in preserving the hypothalamic-pituitary negative feedback loop — a physiological advantage that distinguishes it from exogenous recombinant GH administration.
This item is not currently in stock. Message us on Telegram to check availability or place a request.
Join TelegramSermorelin's most scientifically distinctive property is its preservation of the hypothalamic-pituitary negative feedback loop. Because sermorelin stimulates the pituitary to produce endogenous GH rather than introducing exogenous GH directly, somatostatin can still regulate the system. GH overdoses are physiologically difficult or impossible to achieve, and the pulsatile pattern of GH release is preserved — more closely mimicking normal physiology than constant-infusion exogenous GH.
A 2009 PMC review (Sigalos & Pastuszak) documented that sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing pituitary reserve and preserving more of the GH neuroendocrine axis — which is among the first hormonal axes to decline during aging. This 'pituitary recrudescence' effect has been proposed as a key advantage over GH replacement therapy in aging research.
The GHRH axis shows age-related functional decline earlier than many other neuroendocrine systems, and maintaining its activity may have downstream effects on IGF-1 levels, body composition, sleep architecture, and cognitive function — all associated with GH signalling in the published literature.
Exogenous recombinant GH (rhGH) bypasses the pituitary entirely, delivering a fixed pharmacological GH dose that produces supraphysiological peaks and non-pulsatile exposure. This suppresses endogenous GH axis activity over time through feedback inhibition.
Sermorelin, by contrast, stimulates the pituitary's own output within its physiological capacity. The maximum GH produced is limited by the pituitary's reserve and subject to somatostatin suppression — meaning the system cannot be 'floored' in the same way exogenous GH can.
Sermorelin's well-characterised pharmacology and historical FDA approval status make it a reference compound in growth hormone axis research. Its short half-life (~11 minutes) requires either frequent dosing or modified delivery strategies, which has driven interest in longer-acting GHRH analogues (CJC-1295) as alternatives.
In ageing biology research, sermorelin has been used as a reference compound for studying the relationship between GHRH axis function and age-associated physiological markers in preclinical and observational study contexts.